#### Draft program as of 21 June 2024

#### 10<sup>th</sup> September:

Regulatory Dinner: The regulatory members of the Scientific Committee are organizing a regulatory gettogether in the margins of the workshop to foster the international exchange within this group. All regulators and HTA assessors are cordially invited to this (self-payed) event. The get-together will take place in a relaxed and informal atmosphere in a restaurant on Sept 10<sup>th</sup>, 2024 at 19:00 CEST on the evening before the workshop. Please book your travel accordingly. To register please fill out the following form. Details will follow via email to all who registered. To facilitate the planning please register no later than 28 August 2024. In case of questions please reach out to the organizers Heidi Mestl (Heidi.Mestl@legemiddelverket.no) or Benjamin Hofner (Benjamin.Hofner@pei.de).

11th September 2024, 0830-1700 (+2h wine tasting), Day 1

Time	Duration (mins)	Presentation	
8:30-8:45	15	Opening remarks	
		Egbert Biesheuvel (EFSPI President, Senior Director Viatris)	
8:45-10:45	120	Session 1: Fast to market vs. robustness of the data	
		Talk 1: How much it matters to be first in class. And how can you catch up? Speaker: Jenny Devenport (Roche)	
		Talk 2: Conditional marketing authorisation. Speaker: Eva Skovlund, NOMA	
		Talk 3: CLL11 – a trial tailored to answer questions from many stakeholders efficiently. Elina Asikanius (Fimea), Kaspar Rufibach (Roche)	
		Panel discussion with the audience	
10.45-11.15	30	Coffee break	
11:15-13:15	120	Short topics (20 mins per topic): Present problem on 2-3 slides and receive input from a panel of regulators	
		Confirmed panellists: Benjamin Hofner, Lukas Aguirre Davila, Heidi Meistl, Kit Roes, Bergrun Magnusdottir, Andreas Brandt, Florian Kilngmuller, Eva Skovlund, Khadija Rantell	
		Chairs: Elina Asikanius (fimea, EMA) and Kaspar Rufibach (Roche)	
		Topic 1:	
		Topic 2:	
		Topic 3:	
		Topic 4:	
		Topic 5:	
		Topic 6:	
		Please send proposals by 15 August to <a href="mailto:hlyn@novonordisk.com">hlyn@novonordisk.com</a>	

13:15-14:45	90	Lunch break and poster session: ESIGs and EFSPI Working Groups	
14:45-17:00	135	Session 2: Estimands – Celebrating the 5th anniversary of ICH E9(R1) – what have we learned and where do we need to go?	
		Talk 1: What has improved and what new issues did we uncover and what issues are we still ignoring? Speakers: Frank Bretz, Novartis and Rob Hemmings, Consilium	
		Talk 2: How has the estimand framework impacted the regulatory process in FDA? Are we discussing the clinical question of interest? What do stakeholders need from statisticians to embrace the framework? Speaker: Miya Okada Paterniti, MD, FDA	
		Panel discussion with audience Panellists: Florian Lasch, EMA	
17:00-19:00	120	Wine tasting organised by Hans Ulrich Burger (Roche) and Emmanuel Zuber (Novartis)	

### 12<sup>th</sup> September 2024, 0830-1700, Day 2

Time	Duration (mins)	Presentation	
8.30-10.00	90	Session 3: How can statisticians navigate the interface between the EU Joint Clinical Assessment and EMA regulatory assessment?	
		Panel discussion with the audience	
10.00-10.30	30	Coffee break	
10:30-12:30	120	Session 4: Patient centricity	
		Chairs:	
		Talk 1: ICH E22 General Considerations for Patient Preference Studies.  Speaker: Dr Francesco Pignatti, Rapporteur (EC)	
		Talk 2: Summary of Product Characteristics, section 5.1; what can the industry statistician do to ensure patient relevant data is included? Speaker: Elina Asikanius, fimea.	
		Talk 3: Industry case study. How a patient preference trial impacted the approval/SmPC. Speaker: Brett Hauber, Pfizer	
		Talk 4: Selecting the treatment – my patient and statistician perspectives. Speaker: Anna Wiksten	
		Panel discussion with the audience	
12.30-14.00	90	Lunch break	
14:00-15:30	90	Session 5: Openstatsware - How can we build a scalable ecosystem?	
		Talk 1: General GCP principles with focus on software. Speaker: Sarianne Päivike, (fimea)	

		Talk 2: Openstatsware: introduction and vision/industry case. Speaker: Daniel Sabanés Bové, Roche  Panel discussion with the audience Panelists: Tobias Fellinger, EMA
15:30-17:00	90	Session 6: Regulatory updates  EMA Speaker: Kit Roes Radboud University, Netherlands
		Q&A

### 13<sup>th</sup> September 2024, 0830-1200, Day 3

Time	Duration (mins)	Presentation
8.30-9.45	75	Session 7: Regulatory landscape in China
		Q&A
9.45-10.15	30	Coffee break
10.15-11.45	90	Session 8: The role of innovative statistical methods in pan-European HTA
		Panel discussion with the audience
11.45-12.00	15	Closure  Helle Lynggaard (Novo Nordisk, Local Organizing and Scientific Committee)

#### **Confirmed posters:**

ESIG/EFSPI Working Group	Title	Author(s)/Presenter(s)
Estimand Implementation Working Group (EIWG)		
EIWG – reporting sub-team		
EIWG – estimands in non- inferiority trials		Sue McKendrick (PPD), David Wright (AstraZeneca), Helle Lynggaard (Novo Nordisk), Chrissie Fletcher (GSK) and Sunita Rehal (GSK)
EIWG – intercurrent events		

Launch & Lifecycle		Jenny Devenport (Roche) and Yulia Dyachkova (Merck)
Regulatory ESIG	Regulatory Special Interest Group	Alessandro Previtali (BMS), Mark Whitlock (GSK) and Yolanda Barbachano (Biontech)
Statistics Methods Leaders		